| ABO |
P16442
|
ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase
|
Enzyme
|
|
0.427 |
0.885 |
| CECR |
|
cat eye syndrome chromosome region
|
|
|
0.599 |
0.731 |
| FPR1 |
P21462
|
formyl peptide receptor 1
|
G-protein coupled receptor
|
|
0.576 |
0.769 |
| HLA-DPB2 |
|
major histocompatibility complex, class II, DP beta 2 (pseudogene)
|
|
|
0.743 |
0.500 |
| IFNA1 |
P01562
|
interferon alpha 1
|
|
|
0.371 |
0.923 |
| IFNA13 |
P01562
|
interferon alpha 13
|
|
|
0.374 |
0.923 |
| MMP12 |
P39900
|
matrix metallopeptidase 12
|
Enzyme
|
|
0.484 |
0.885 |
| COX1 |
P00395
|
cytochrome c oxidase subunit I
|
Enzyme
|
|
0.441 |
0.885 |
| COX2 |
P00403
|
cytochrome c oxidase subunit II
|
Enzyme
|
|
0.352 |
0.962 |
| NM |
|
neutrophil migration
|
|
|
0.473 |
0.808 |
| PECAM1 |
P16284
|
platelet and endothelial cell adhesion molecule 1
|
Cell adhesion
|
|
0.426 |
0.846 |
| RNASE2 |
P10153
|
ribonuclease A family member 2
|
|
|
0.621 |
0.692 |
| SRY |
Q05066
|
sex determining region Y
|
Transcription factor
|
|
0.456 |
0.808 |
| ST2 |
|
suppression of tumorigenicity 2
|
|
|
0.576 |
0.692 |
| TRA |
P0DSE1
|
T cell receptor alpha locus
|
|
|
0.628 |
0.577 |
| LOH19CR1 |
|
loss of heterozygosity, 19, chromosomal region 1
|
|
|
0.569 |
0.808 |
| UHRF1 |
Q96T88
|
ubiquitin like with PHD and ring finger domains 1
|
|
|
0.540 |
0.692 |
| MEG3 |
|
maternally expressed 3
|
|
|
0.471 |
0.846 |
| GAS5 |
|
growth arrest specific 5
|
|
|
0.497 |
0.808 |
| PWAR1 |
|
Prader Willi/Angelman region RNA 1
|
|
|
0.490 |
0.769 |
| PTPRVP |
|
protein tyrosine phosphatase receptor type V, pseudogene
|
|
|
0.705 |
0.577 |
| COPD |
|
Pulmonary disease, chronic obstructive, severe early-onset
|
|
|
0.456 |
0.885 |
| NEAT1 |
|
nuclear paraspeckle assembly transcript 1
|
|
|
0.502 |
0.769 |
| MALAT1 |
|
metastasis associated lung adenocarcinoma transcript 1
|
|
|
0.435 |
0.846 |
| MIR10A |
|
microRNA 10a
|
|
|
0.513 |
0.846 |